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Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210 S197Removing co-cultured T and NK like T cells by CD3-
depletion during the expansion phase was possible and
resulted in a higher purity of NK cells (56 - 96%). The cells
retained their proliferative capacity after depletion and
expansion factors of 30-156-fold were obtained.
Flow cytometry analysis revealed comparable expression
of CD16, NKp30, NKp46 and NKG2D for manually or auto-
matically expanded NK cells either from CD3-depleted or
undepleted cultures.
Results show that large scale automation of NK cell
expansion is possible by use of the CliniMACS Prodigy. CD3
depletion of unwanted T and NK like T cells during culture is
feasible.170
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Background: Successful vascularized composite allograft
(VCA) transplantation requires life-long treatment
combining more than two immunosuppressive agents and
pose signiﬁcant risks and side effects. Cell based therapies
are a new promising approach for tolerance induction that
could prevent or reduce negative impact of life-long immu-
nosuppression. Bone marrow transplantation has already
been tested for solid organs, face and upper extremity
transplants for modulation of immune responses. We
propose a new cellular therapy based on the ex vivo created
donor-recipient chimeric cells as an alternative approach to
bone marrow based therapies in support of VCA. The aim of
this preclinical study was to create and characterize in vitro
the phenotype, genotype and viability of fused human di-
chimeric cells (dCC).
Materials and Methods: Fourteen ex vivo fusions of human
umbilical cord blood (UCB) cells were performed. Mono-
nuclear cells (MNCs) were isolated from UCB originating
from 2 different donors. Next MNCs were stained separately
by PKH26 and PKH67. Fusion procedure was performed
using polyethylene glycol (PEG) technique. Double PKH26
and PKH67 stained cells were sorted out and subjected to
further assessments. Flow cytometry (FC), (CD3, CD4, CD8,
CD19, CD34 and CD90, viability test), confocal microscopy
(CM), ﬂuorescent lymphocytotoxicity assay (LCT), PCR-
reverse sequence-speciﬁc oligonucleotide probe (PCR-
rSSOP) and short tandem repeat- PCR (STR-PCR) and
colony- forming unit (CFU) assay were assessed to charac-
terize the phenotype and genotype of fused human
chimeric cells.
Results: FC and CM analysis conﬁrmed UCB fusion and
creation of human dCC. Using LCT assay we determined that
human dCC are sharing HLA class I and class II antigens
speciﬁc for both types of UCB donors used for fusion. Results
of the LCT test were conﬁrmed by rSSOP and STR assaywhich
revealed that fused dCC were in fact originating (39-51%)
from each of the UCB donors. After fusion 96-99% of cells
were viable. Preliminary phenotype characterization showed
expression of all assessed markers on the surface of dCC. CFU
assay conﬁrmed the presence and functionality of dCC
mature progenitor comparable to untreated cord blood
progenitor cells.Conclusions: We successfully conﬁrmed feasibility of ex
vivo fusion of UBC cells leading to creation of human
fused dCC. We characterized cell phenotype and viability.
This unique concept of di-chimeric cell therapy introduces
new applications in transplant surgery. The ultimate goal
is to induce tolerance in VCA transplants.171
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To date, despite recent progress in the treatment of
Plasma Cell Myeloma (PCM), it remains an incurable
disease in which prolonged therapy (maintenance)
appears to be beneﬁcial. Th1 immunity is critical in tumor
immune surveillance and immune mediated tumor eradi-
cation, in particular of PCM. Immune reconstitution deﬁ-
ciency following autologous stem cell transplantation
(AHCT) is believed to be a barrier to tumor eradication.
Immunotherapy efforts and attempts to boost immunity
with adoptive cell transfer have been thwarted by the
short life span of the transferred cells. In our pre-clinical
work, we found that human Th1/Tc1 lymphocytes, gener-
ated ex vivo in the presence of rapamycin (“T1.R”), pro-
longed engraftment in a human-into-murine model of
xenogeneic GVHD. Based on these data, we have imple-
mented a phase I, dose escalation clinical trial to evaluate
the feasibility and toxicity of the adoptive transfer of
autologous T1.R lymphocytes following AHCT in subjects
with recurrent or newly diagnosed high-risk PCM.
Subjects are receiving T1.R cells at doses ranging from
1x105 to 45x106 cells/kg. To generate T1.R cells, lympho-
cytes are collected by steady-state apheresis prior to
hematopoietic progenitor cell mobilization/collection;
elutriated lymphocytes are then cultured for 6 days using
CD3, CD28 co-stimulation, polarizing cytokines (IL-2 + IFN-
alpha), and high-dose rapamycin (1 mmol) and adminis-
tered 6-8 weeks following AHCT. T1.R cells were generated
in all cases (n¼13); eight subjects have safely received
T1.R cells at a median of 55 days post-AHCT. There have
been no clinical adverse events attributable to the T1.R
cells, and there has been no post-infusion serum elevation
of the following cytokines tested at 1h, 4h, 24h, 48h, 72h
and 7, 14 and 28 days: GM-CSF, INF-g, IL-1b, IL-6, IL-8 and
TNF-a. Current accrual is proceeding at the 5 x 106 cells/
kg cohort. T1.R cell recipients have in general shown
a disease response (see Table), although the median post-
